ArticleJCO precision oncology2017
Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype.
Article in JCO precision oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Genetic characteristics and targeted treatments of primary bladder and urachal adenocarcinomas: a systematic review with pooled descriptive genomic analyses.Cancer metastasis reviews · 2026Pooled it
- Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma.Frontiers in pharmacology · 2023Pooled it
- Metastatic Urachal Carcinoma With Microsatellite Stability and Low Tumor Mutational Burden Achieving a Durable Response to Pembrolizumab After Platinum Failure.IJU case reports · 2026Article
- Efficacy and safety of camrelizumab plus apatinib in advanced urachal cancer (RUN-SC-0102): a single-arm, multicentre, phase 2 trial in China.EClinicalMedicine · 2026Article
- Patient-derived d-MMR/MSI phenotype urachal cancer organoids for personalized drug screening.Frontiers in oncology · 2026Article
- Treatment outcomes and next-generation sequencing of a rare malignancy - urachal carcinoma: case report and literature review.Frontiers in oncology · 2026Article
- Article
- Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.European urology · 2025Article
- Comprehensive analysis of targetable mutations and tumor microenvironment in urachal cancer.NPJ precision oncology · 2025Article
- Spatially fractionated radiotherapy combined with CapeOX and bevacizumab for postoperative pulmonary metastasis from urachal carcinoma: a case report.Frontiers in oncology · 2025Article
- Surgical treatment of urachal adenocarcinoma with lung metastasis: A case report and literature review.Thoracic cancer · 2024Review
- Modern methods in managing urachal adenocarcinoma.Current urology · 2023Article
- Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma.American journal of clinical pathology · 2022Article
- Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.JCO precision oncology · 2022Article
- Treatment Outcome of Different Chemotherapy in Patients With Relapsed or Metastatic Malignant Urachal Tumor.Frontiers in oncology · 2021Article
- Metastatic Urachal Carcinoma Treated With Several Different Combined Regimens: A Case Report.Frontiers in oncology · 2021Article
- Prevalence of APC and PTEN Alterations in Urachal Cancer.Pathology oncology research : POR · 2020Article
- Comparative genomic profiling of glandular bladder tumours.Virchows Archiv : an international journal of pathology · 2020Article
- Genomic Subtyping in Bladder Cancer.Current urology reports · 2020Review
- Current Understanding of Urachal Adenocarcinoma and Management Strategy.Current oncology reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
Abstract
purposeUrachal adenocarcinoma is a rare type of primary bladder adenocarcinoma that comprises less than 1% of all bladder cancers. The low incidence of urachal adenocarcinomas does not allow for an evidence-based approach to therapy. Transcriptome profiling of urachal adenocarcinomas has not been previously reported. We hypothesized that an in-depth molecular understanding of urachal adenocarcinoma would uncover rational therapeutic strategies. PATIENTS AND
methodsWe performed targeted exon sequencing and global transcriptome profiling of 12 urachal tumors to generate a comprehensive molecular portrait of urachal adenocarcinoma. A single patient with an
resultsUrachal adenocarcinoma closely resembles colorectal cancer at the level of RNA expression, which extends previous observations that urachal tumors harbor genomic alterations that are found in colorectal adenocarcinoma. A subset of tumors was found to have alterations in genes that are associated with microsatellite instability (
conclusionBecause clinical trials are next to impossible for patients with rare tumors, precision oncology may be an important adjunct for treatment decisions. Our findings demonstrate that urachal adenocarcinomas molecularly resemble colorectal adenocarcinomas at the level of RNA expression, are the first report, to our knowledge, of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.